Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications
ConclusionThe evidence suggests that RCI may improve inflammatory and autoimmune disease control and patient quality of life, particularly in complex patients, and yield healthcare cost savings that demonstrate the medicine ’s value.FundingMallinckrodt Pharmaceuticals Inc.
Conclusions: GCP patients (otherwise systemically healthy) were characterized by increased Th17-proinflammatory cell phenotype positive for the IL-23 receptor in peripheral blood. The proportion of Th17 cells that are negative for the IL-23 receptor in the peripheral blood of systemically healthy patients seemed to be unaffected by the presence or absence of chronic periodontitis.
Authors: Kaur P, Kumar P, Randev S, Guglani V Abstract Allergic bronchopulmonary aspergillosis (ABPA) is an immunological disease complicating asthma or cystic fibrosis. An 8-year-old girl with no previous respiratory morbidity was diagnosed with ABPA on the basis of a raised eosinophil count and total and specific serum IgE levels combined with a positive skin-prick test for aspergillus and typical CT images of finger-in-glove hilar opacities and hyperattenuating mucous. She responded to treatment with itraconazole and corticosteroids and remains well. As far as we are aware, she is only the second child to be dia...
Total saponin of Dioscorea collettii attenuates MSU crystal‑induced inflammation via inhibiting the activation of the NALP3 inflammasome and caspase‑1 in THP‑1 macrophages. Mol Med Rep. 2020 Mar 20;: Authors: Wang L, Zhu L, Duan C, Li L, Chen G Abstract Total saponins extracted from Dioscorea collettii (TSD), extracts of the Chinese herb Dioscorea, are thought to exhibit therapeutic benefit in gouty arthritis. However, its exact mechanism remains unclear. The current study aimed to elucidate the underlying mechanisms by investigating the effects of TSD on the inflammation induced by mon...
Publication date: Available online 2 April 2020Source: Life SciencesAuthor(s): Emerson Souza da Rocha, Fabiana de Campos Gomes, Murilo Romano de Oliveira, Ricardo Vinicius Bruneto, Rodrigo Miranda Ramos Borges, Enzo Prandi de Carvalho, Euradir Vitório Angeli-Junior, Glayber Falcão Garcia-Filho, João Pedro Lot Doná, Rodrigo Piloto de Oliveira Batanero, Carla Patrícia Carlos, João Simão de Melo-Neto
In conclusion, AS-IV could decrease the system exposure of triptolide when they are co-administered, and it might work through decreasing the absorption of triptolide by inducing the activity of P-gp. PMID: 32233814 [PubMed - in process]
(BRONX, NY)—April 3, 2020—Montefiore Health System andAlbert Einstein College of Medicine has started treating very sick COVID-19 patients as part of a multicenter trial evaluating a potential therapy for the new disease. The double-blind, placebo-controlled trial is testing whether sarilumab, a drug already approved for treating rheumatoid arthritis, can halt the inflammation that can overwhelm the lungs of COVID-19 patients. A very similar drug yielded promising results in a recent study involving patients in China.
DISCUSSION: Our case highlights how DIL should be on the differential when seemingly disparate symptoms develop in a patient receiving DIL-associated medications. Lupus is one of the "great imitators," in which symptoms can be ascribed to many different underlying causes. Although this patient's presentation may have been confounded by concomitant histoplasmosis, his improvement with cessation of hydralazine treatment argues in favor of DIL. His continued atypical serologic test results could be residual from his DIL and should normalize with time. However, it raises the question whether this bout of DIL has unma...
Those on steroids because of known adrenal disease, and for more common ailments, may need additional'stress'doses of IV corticosteroids in the case of severe infection with COVID-19, endocrinologists urge.Medscape Medical News
Condition: Rheumatoid Arthritis Interventions: Drug: SHR0302; Drug: Placebo Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Condition: Arthritis, Rheumatoid Interventions: Biological: GSK3196165; Drug: csDMARD(s) Sponsors: GlaxoSmithKline; Iqvia Pty Ltd Not yet recruiting
More News: Academies | Arthritis | Autoimmune Disease | Corticosteroid Therapy | Dermatology | Dermatomyositis | Drugs & Pharmacology | Emergency Medicine | Hormones | Lupus | Managed Care | Multiple Sclerosis | Nephrotic Syndrome | Polymyositis | Proteinuria | Rheumatoid Arthritis | Rheumatology | Sarcoidosis | Study